The market size of the US patient registry software is estimated to be USD 0.55 billion in 2025 and is expected to grow by USD 0.60 billion in 2026, to close to USD 1.58 billion in 2035 with a CAGR of 11.02%.
US Patient Registry Software Market Revenue and Trends
In the US, patient registry software offers dedicated solutions to the systematic assembly, management, examination, and reporting of longitudinal patient information and information across diverse sicknesses, conditions, therapies, and results to assist in the generation of real-world evidence, post-market oversight, quality enhancement, research, regulatory filings, value-based care programs, and population well-being management.
The market of the US patient registry software is developing at a very fast pace, owing to the heightened focus on real-world evidence (RWE) in regulatory decision-making, the proliferation of value-based payment models, the need to track rare diseases and chronic conditions, the rising popularity of registry-based studies, and the development of cloud-based, interoperable, and AI-powered registry platforms in healthcare and life sciences ecosystems.
.png)
What are the Factors That Have a Significant Contribution to the Growth of the US patient registry software market?
Demand for high-quality real-world data, which the FDA and CMS focus on RWE to approve drugs, add new labels, and post-approval promises, and value-based care contracts that necessitate outcome monitoring and quality reporting, has led to increased demand for patient registry software products. Both health systems and specialty societies, pharma sponsors, and payers will demand effective and compliant registry solutions in order to pool structured longitudinal data as pressure continues to mount on them to demonstrate their effectiveness, safety, and cost-efficiency.
Innovations such as FHIR-based interoperability, AI-based data standardization and natural language processing of unstructured sources, automated patient-reported outcomes (PRO) capture, predictive analytics to identify cohorts, and cloud-native computing with increased security and scalability have been introduced as a result of technological advances and enhance the quality and usability of the data. There are also other causes, such as heightened regulatory incentives to join the registry, broader reimbursement of registries to support quality improvement, strong funding of rare disease and chronic condition registries, and an increase in the number of academic, pharmaceutical, and payer engagements to use registries to generate evidence.
Segment Insight
By Product Type
Cloud based patient registry systems owned by far the largest portion of the US patient registry software market as of 2025, with requirements to support multi-center data collection, real-time analytics, and a smooth integration with EHRs and claims systems driving continued innovation in AI-assisted data curation, automated integration with PROs and RWE dashboards cited by large proportions of registry administrators and researchers as being superior to their traditional methods of generating evidence and increasing data completeness.
By Distribution Channel
The biggest market share is in direct sales and SaaS subscription processes, which are major mechanisms of enterprise implementations, personalized registry environments, data relocation of the existing systems and continued provision of regulatory compliance and analytics demand. These channels have become the choice for implementing patient registry software since they offer professional skills in HL7/FHIR integration, validation rule configuration, security certification, and management of partnerships with sponsors and societies.
Report Scope
Feature of the Report | Details |
Market Size in 2026 | USD 0.60 billion |
Projected Market Size in 2035 | USD 1.58 billion |
Market Size in 2025 | USD 0.55 billion |
CAGR Growth Rate | 11.02% CAGR |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Key Segment | By Registry Type, Software Type, Deployment Model, Functionality, End User and Region |
Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Recent Developments
In November 2025: ArborMetrix enhanced its cloud-based registry platform with new generative AI capabilities for automated cohort phenotyping and real-time RWE reporting, supporting faster post-market surveillance and value-based care outcome tracking for multiple US specialty societies and health systems.
List of the prominent players in the US Patient Registry Software Market:
IQVIA Holdings Inc.
Optum Inc. (UnitedHealth Group)
Premier Inc.
Syneos Health
FIGmd Inc.
ImageTrend Inc.
DACIMA Software Inc.
Global Vision Technologies Inc.
OpenText Corporation
Liaison Technologies
Others
The US Patient Registry Software Market is segmented as follows:
By Registry Type
Disease Registries
o Cancer Registries
o Cardiovascular Registries
o Diabetes Registries
o Rare Disease Registries
o Immunization Registries
Product Registries
o Medical Device Registries
o Pharmaceutical Product Registries
Health Services Registries
By Software Type
Standalone Software
Integrated Software
By Deployment Model
On-Premise
Cloud-Based
Hybrid
By Functionality
Population Health Management
Medical Research & Clinical Studies
Quality Measurement & Reporting
Patient Care Management
By End User
Government Agencies & TPAs
Hospitals & Medical Practices
Pharmaceutical & Biotechnology Companies
Medical Device Companies
Research Organizations
